Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
POAI logo POAI
Upturn stock ratingUpturn stock rating
POAI logo

Predictive Oncology Inc (POAI)

Upturn stock ratingUpturn stock rating
$0.87
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: POAI (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $3

1 Year Target Price $3

Analysts Price Target For last 52 week
$3 Target price
52w Low $0.55
Current$0.87
52w High $2.25

Analysis of Past Performance

Type Stock
Historic Profit 8.02%
Avg. Invested days 28
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 8.89M USD
Price to earnings Ratio -
1Y Target Price 3
Price to earnings Ratio -
1Y Target Price 3
Volume (30-day avg) 1
Beta 1.19
52 Weeks Range 0.55 - 2.25
Updated Date 08/15/2025
52 Weeks Range 0.55 - 2.25
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.13

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -2073.29%

Management Effectiveness

Return on Assets (TTM) -73.2%
Return on Equity (TTM) -490.37%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 10499739
Price to Sales(TTM) 5.14
Enterprise Value 10499739
Price to Sales(TTM) 5.14
Enterprise Value to Revenue 6.31
Enterprise Value to EBITDA -0.51
Shares Outstanding 10222200
Shares Floating 8826496
Shares Outstanding 10222200
Shares Floating 8826496
Percent Insiders 1.11
Percent Institutions 1.96

ai summary icon Upturn AI SWOT

Predictive Oncology Inc

stock logo

Company Overview

overview logo History and Background

Predictive Oncology Inc. (formerly known as Cancer Research Technologies, Inc.) was founded with the aim of developing advanced technologies to improve cancer treatment outcomes. The company has evolved through strategic acquisitions and a focus on predictive models and personalized medicine.

business area logo Core Business Areas

  • Drug Discovery & Development Services: Offers drug discovery and development services using its AI-powered platform, PeptiDream, and other technologies, with a focus on identifying and validating drug candidates for various cancers.
  • TumorGenesis: Offers a 3D tumor microenvironment platform that simulates the conditions within a tumor, enabling more accurate drug testing and prediction of patient responses. This includes testing and development services for pharmaceutical companies.
  • Skyline Medical: Focuses on the STREAMWAY System, a fully automated, direct-to-drain medical fluid disposal system.

leadership logo Leadership and Structure

The leadership team includes executives with experience in biotechnology, pharmaceuticals, and finance. The organizational structure is composed of research and development, commercial operations, and administrative functions.

Top Products and Market Share

overview logo Key Offerings

  • PeptiDream Platform: AI-powered platform used for drug discovery and development. Competitors include Schru00f6dinger and Exscientia. Difficult to determine specific market share but is a growing market.
  • TumorGenesis 3D Microenvironment: A 3D tumor microenvironment platform for drug testing. Competitors include Insphero and MIMETAS. Similar to PeptiDream Market share is difficult to determine.
  • STREAMWAY System: Fully automated medical fluid disposal system. Competitors include Stryker and Cardinal Health. Revenue from this product provides a stable revenue base, but market share is relatively small compared to larger players in medical device market.

Market Dynamics

industry overview logo Industry Overview

The industry is characterized by increasing demand for personalized medicine and advanced drug discovery platforms. Oncology is a major focus area, with significant investments in research and development.

Positioning

Predictive Oncology Inc. positions itself as a leader in AI-powered drug discovery and development services, with a focus on improving cancer treatment outcomes through personalized medicine.

Total Addressable Market (TAM)

The global oncology market is projected to reach hundreds of billions of dollars. Predictive Oncology Inc. is positioned to capture a share of this market through its drug discovery and development services, and predictive technologies.

Upturn SWOT Analysis

Strengths

  • AI-powered drug discovery platform
  • 3D tumor microenvironment platform
  • Established customer base
  • STREAMWAY System provides recurring revenue

Weaknesses

  • Limited financial resources
  • Reliance on partnerships for drug development
  • History of operating losses
  • Stock price volatility

Opportunities

  • Increasing demand for personalized medicine
  • Partnerships with pharmaceutical companies
  • Expansion into new markets
  • Advancements in AI and machine learning

Threats

  • Competition from larger pharmaceutical companies
  • Regulatory hurdles
  • Technological advancements by competitors
  • Economic downturn

Competitors and Market Share

competitor logo Key Competitors

  • CRIS
  • VIRI
  • CLVS

Competitive Landscape

Predictive Oncology Inc. faces competition from larger pharmaceutical companies and biotechnology firms. The company's AI-powered platform and 3D tumor microenvironment platform provide a competitive advantage, but limited financial resources pose a challenge.

Major Acquisitions

Skyline Medical

  • Year: 2019
  • Acquisition Price (USD millions): 11.2
  • Strategic Rationale: Acquisition of Skyline Medical added a stable revenue base from the STREAMWAY System, diversifying the company's revenue streams.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been inconsistent, with periods of rapid expansion followed by periods of contraction.

Future Projections: Future growth projections depend on successful partnerships and commercialization of its drug discovery and development services. Analyst estimates vary widely.

Recent Initiatives: Recent strategic initiatives include expansion of its AI-powered platform, and collaboration agreements with pharmaceutical companies.

Summary

Predictive Oncology Inc. is attempting to leverage its AI and 3D tumor modelling to enhance cancer treatment and discovery. While they have some innovative technologies, they have challenges in reaching the profitability and have history of operating losses. They need to improve the bottom line and make improvements to keep the company solvent. The company's dependence on partnerships could make it vulnerable to changes in the biotech climate.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings (10-K, 10-Q), Press Releases, Analyst Reports, Market Research Reports

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share percentages are estimates based on available data and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Predictive Oncology Inc

Exchange NASDAQ
Headquaters Pittsburgh, PA, United States
IPO Launch date 2018-01-29
CEO & Chairman Mr. Raymond F. Vennare
Sector Healthcare
Industry Health Information Services
Full time employees 23
Full time employees 23

Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of cancer therapies. It operates through two segments, Pittsburgh and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples. This segment also creates proprietary 3D culture models used in drug development. Its Eagan segment produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Pittsburgh, Pennsylvania.